Medical network - June 30, recently, CCTV financial channel "for the first time" aired a "focus on low prices medicine survival predicament" reports, the report from the recent health development planning commission of guangdong province announced a v of the drug trade in batches of not in accordance with the contract delivery and not timely supply, started list.
According to the statistics, in this list, there are a total of 1,004 articles or products that are not timely, most of which are low-price drugs, involving more than 100 pharmaceutical companies. Why do you have such a wide range of low-price drugs? The fundamental reason is that the price of raw materials has skyrocketed.
▍ API is monopoly price
According to the report, the product of a particular drug firms eighty percent belong to the low price drugs, are now facing out of stock, some even have shut down - among them, the main product hydrochloric acid naphthyl methyl thiazole moiety of active pharmaceutical ingredients from monopoly before 6000 yuan a kilogram, up to now 20000 yuan per kilogram, raw material prices make its product cost as a whole increased by 40% to 40%.
Also have chief discloses drug firms, the more popular low-priced medicine, all suffered API rise considerably, or at least a few times or more commonly, some raw materials even in nearly three years of time, or 100 times.
In fact, as early as the beginning of 2016's "two sessions", sichuan good doctor pharmaceutical group co., LTD., chairman of the board of directors can GengFu said, in recent years, the pharmaceutical industry API monopoly phenomenon is more serious, which is one of the main factors that cause drug prices.
, for example, in February 10, published by the state administration for industry and commerce of the competition law enforcement announcement no. 4, 2017 emerging elite pharmaceutical co., LTD. (wuhan) abuse of dominant market position case ", in the case of the salicylic acid methyl ester will several API production enterprises of the national total generation rights, possession of the API after all the market share, methyl salicylate drug substances by 20000 yuan/tons up to 60000 yuan/ton, the lowest price 500000 yuan/ton.
In addition, in recent years, the environmental protection of the API industry has been a huge pressure, which is also an important reason for the large price increase of API.
Released in November last year, hebei atmosphere do 2 scheduling for the prevention and control of atmospheric pollution ", then, a scheduling order of the shijiazhuang city prevention and control of atmospheric pollution brings heavy shock to the pharmaceutical industry, production requires all pharmaceutical industry in the city of shijiazhuang in production without approval by the municipal government, to return to work.
Shijiazhuang is one of the important production bases of raw materials, which has accumulated a number of well-known pharmaceutical manufacturers including shi yao and north China pharmaceutical.
Under the pressure of environmental protection, the rising cost of raw materials has been inevitable, and the pressure of price increases will be extended to the manufacturers of pharmaceutical preparations.
At the same time, combined with API monopolies emerge in endlessly, and price is not available, chemical medicine preparations production enterprises, especially those cheap medicine production enterprises, not in accordance with the contract, because it is easy to understand.
▍ proprietary Chinese medicine costs skyrocket 50 times
In addition to western medicine, Chinese medicine is also facing rising costs of raw materials, and many drugs are on the verge of breakage, according to CCTV.
Southern shandong pharmaceutical group chairman gui-min zhang said, like the scorpion centipede three ingredients, prices have a lot of times longer, prices are few yuan before, are now thousands of yuan, to turn over 20 or 30 times, some even is 50 times.
Some drug companies in shandong director, told reporters that they enterprises of proprietary Chinese medicine there are dozens of varieties, most of them are listed in the 90 s, and now the main raw material prices of these drugs in rising year after year accounted for ninety percent.
Although the cost of raw materials is increasing year by year, many drugs still follow the price of more than a decade ago, or only slightly. Therefore, for some raw materials cost too high, inevitable loss of medicine, can only suspend production.
This is why the cheap and cheap Chinese medicine, like compound Dan ginseng, has become the low price medicine that the market has not seen very much. In an era of soaring costs and weak profits, many Chinese drug makers have lost the incentive to produce these cheap, medium-priced medicines.
Aiming at the problem of low medicine out of stock, the reform of the state council leading group of the advisory committee liu gg said in an interview, shortage of cheap drugs is periodic medical field in a problem, should be from medical service chain of front-end and terminal two dimensions to solve.
Liu gg proposal, in the tender purchase, the government in price negotiations should leave some space to the enterprise, or for business judgment in the next few years, raw material market conditions change of the demand for drugs and patient population, in order to give a reasonable price space. |
